OncoMarks

Impact of number of bone metastases on cancer control outcomes in mHSPC, independent of the axial-skeleton CHAARTED definition

Median time to CRPC was 28.4 months for 1 to 3 bone metastases, 17.3 months for 4 to 7 bone metastases, and 16.2 months for ≥8 bone metastases (P < 0.01)...

Prostate Cancer - mCRPCProstate Cancer - mHSPC

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration

The meta-analysis of six trials (472 patients) comparing MDT plus SOC versus SOC showed that MDT was associated with significantly improved progression-free ...

CNS Tumors - Low Grade Glioma

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)

After a median follow-up of 13.1 years, there was no significant difference in progression-free survival (PFS) or overall survival (OS) between the two treat...

Breast Cancer - Systemic Tx - Her2+Breast Cancer - Systemic Tx - HR+

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

After a median follow-up of approximately 60 months, the 5-year overall survival rate was 100% in the ET arm versus 97.9% in the paclitaxel arm. The 5-year e...

Lung Cancer - NSCLC - Definitive CRT

Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non–Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART)

The study met its primary endpoint with a 2-year progression-free survival (PFS) of 39% (one-sided CI, 29 to 100) compared to the historical control of 20%. ...

Bladder Tumors - Locally-Advanced

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer

At 2 years, estimated event-free survival was 79.4% with enfortumab vedotin–pembrolizumab and 66.2% with cisplatin–gemcitabine (hazard ratio for event or...

Ovarian Cancer - Locally-AdvancedOvarian Cancer - Metastatic

Trending Trials

Most liked trials

View Details 2026/07/20 Ali Aqamolaei

Final Results From the ATALANTE/ENGOT-ov29 Randomized Phase III Trial of Atezolizumab, Bevacizumab, and Platinum-Based Therapy for Late-Relapsing Recurrent Ovarian Cancer

At 5 years' median follow-up, the median overall survival was 35.8 months with atezolizumab-containing therapy versus 30.6 months with standard therapy i...

Breast Cancer - Early StageBreast Cancer - Locally-Advanced

—

Breast Cancer Atlas for Radiation Therapy Planning: Consensus Definitions

This consensus guideline provides detailed anatomical boundaries and contouring principles for breast cancer radiation therapy planning. For intact breast af...

View Details 2026/06/06 Ali Aqamolaei

Colorectal Cancer - Early StageColorectal Cancer - Locally-Advanced

View Details 2026/05/30 Ali Aqamolaei

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial

With a median follow-up of 113 months and 1,255 OS events, 5-year OS for 3 versus 6 months of treatment was 82.4% in both groups (HR, 0.96 95% CI, 0.86 to 1....

Head and Neck - Nasopharyngeal

2021

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial

At a median follow-up of 38 months, failure-free survival at 3 years was significantly higher in the metronomic capecitabine group (85.3%) versus the standar...

View Details 2026/05/29 Ali Aqamolaei

Breast Cancer - Metastatic - Her2+

2025

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

At interim analysis, trastuzumab deruxtecan plus pertuzumab significantly improved median progression-free survival (40.7 months) compared to THP (26.9 month...

View Details 2026/05/29 Shakiba Sheykholeslamy

View Details 2026/02/15 Ehsan Saraee

2023

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Of 1,305 patients, 1,005 (77%) had high-volume disease and 912 (70%) had high-risk disease. Darolutamide increased overall survival (OS) versus placebo in pa...

OncoMarks Favorites

Most bookmarked trials across users

Impact of number of bone metastases on cancer control outcomes in mHSPC, independent of the axial-skeleton CHAARTED definition

Median time to CRPC was 28.4 months for 1 to 3 bone metastases, 17.3 months for 4 to 7 bone metastases, and 16.2 months for ≥8 bone metastases (P < 0.01)...

Prostate Cancer - mCRPCProstate Cancer - mHSPC

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration

The meta-analysis of six trials (472 patients) comparing MDT plus SOC versus SOC showed that MDT was associated with significantly improved progression-free ...

CNS Tumors - Low Grade Glioma

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)

After a median follow-up of 13.1 years, there was no significant difference in progression-free survival (PFS) or overall survival (OS) between the two treat...

Breast Cancer - Systemic Tx - Her2+Breast Cancer - Systemic Tx - HR+

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

After a median follow-up of approximately 60 months, the 5-year overall survival rate was 100% in the ET arm versus 97.9% in the paclitaxel arm. The 5-year e...

Lung Cancer - NSCLC - Definitive CRT

Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non–Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART)

The study met its primary endpoint with a 2-year progression-free survival (PFS) of 39% (one-sided CI, 29 to 100) compared to the historical control of 20%. ...

Bladder Tumors - Locally-Advanced

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer

At 2 years, estimated event-free survival was 79.4% with enfortumab vedotin–pembrolizumab and 66.2% with cisplatin–gemcitabine (hazard ratio for event or...

Highlights

Notable recent publications

Impact of number of bone metastases on cancer control outcomes in mHSPC, independent of the axial-skeleton CHAARTED definition

Median time to CRPC was 28.4 months for 1 to 3 bone metastases, 17.3 months for 4 to 7 bone metastases, and 16.2 months for ≥8 bone metastases (P < 0.01)...

Prostate Cancer - mCRPCProstate Cancer - mHSPC

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration

The meta-analysis of six trials (472 patients) comparing MDT plus SOC versus SOC showed that MDT was associated with significantly improved progression-free ...

CNS Tumors - Low Grade Glioma

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)

After a median follow-up of 13.1 years, there was no significant difference in progression-free survival (PFS) or overall survival (OS) between the two treat...

Breast Cancer - Systemic Tx - Her2+Breast Cancer - Systemic Tx - HR+

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

After a median follow-up of approximately 60 months, the 5-year overall survival rate was 100% in the ET arm versus 97.9% in the paclitaxel arm. The 5-year e...

Lung Cancer - NSCLC - Definitive CRT

Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non–Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART)

The study met its primary endpoint with a 2-year progression-free survival (PFS) of 39% (one-sided CI, 29 to 100) compared to the historical control of 20%. ...

Bladder Tumors - Locally-Advanced

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer

At 2 years, estimated event-free survival was 79.4% with enfortumab vedotin–pembrolizumab and 66.2% with cisplatin–gemcitabine (hazard ratio for event or...